Erica Taylor returned to Genentech in 2021 as Head of Oncology Strategy and Chief of Staff, Global Product Strategy. In 2022 she became Genentech’s first Chief Marketing Officer and Vice President. Erica most recently served as the Executive Director, COVID-19 Marketing at Gilead Sciences, where she led the US commercial marketing build-out for the launch of remdesivir/VEKLURY, the first FDA-approved therapeutic to treat hospitalized COVID-19 patients.
Prior to this, Erica spent a decade at Genentech, where she began as a Market Planning Manager and served in four additional roles, ending as Marketing Director, Biology. Her responsibilities at Genentech included developing marketing strategy for oncologic therapies in development and leading market analysis, forecasting, and strategic efforts for a product in development. Erica previously spent three years in the Strategy and Portfolio Analysis group within the consulting practice of IMS Health and as the first Director of Diversity and Outreach Programs at Stanford University.
She received a B.S. in from the University of Michigan and a Ph.D. in Immunology at the Stanford University School of Medicine. She has since attended the Columbia Business School and received a Certificate in Business Excellence (CIBE), and participated in the Genentech Leadership for Executive Advancement and Development (gLEAD) Program.
Prior to this, Erica spent a decade at Genentech, where she began as a Market Planning Manager and served in four additional roles, ending as Marketing Director, Biology. Her responsibilities at Genentech included developing marketing strategy for oncologic therapies in development and leading market analysis, forecasting, and strategic efforts for a product in development. Erica previously spent three years in the Strategy and Portfolio Analysis group within the consulting practice of IMS Health and as the first Director of Diversity and Outreach Programs at Stanford University.
She received a B.S. in from the University of Michigan and a Ph.D. in Immunology at the Stanford University School of Medicine. She has since attended the Columbia Business School and received a Certificate in Business Excellence (CIBE), and participated in the Genentech Leadership for Executive Advancement and Development (gLEAD) Program.
Speaking In
1:00 PM - 2:00 PM
Monday, June 5
